首页> 外文期刊>Small >Aptamer-Engineered Natural Killer Cells for Cell-Specific Adaptive Immunotherapy
【24h】

Aptamer-Engineered Natural Killer Cells for Cell-Specific Adaptive Immunotherapy

机译:适用于细胞特异性自适应免疫疗法的适体工程的天然杀伤细胞

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Natural killer (NK) cells are a key component of the innate immune system as they can attack cancer cells without prior sensitization. However, due to lack of cell-specific receptors, NK cells are not innately able to perform targeted cancer immunotherapy. Aptamers are short single-stranded oligonucleotides that specifically recognize their targets with high affinity in a similar manner to antibodies. To render NK cells with target-specificity, synthetic CD30-specific aptamers are anchored on cell surfaces to produce aptamer-engineered NK cells (ApEn-NK) without genetic alteration or cell damage. Under surface-anchored aptamer guidance, ApEn-NK specifically bind to CD30-expressing lymphoma cells but do not react to off-target cells. The resulting specific cell binding of ApEn-NK triggers higher apoptosis/death rates of lymphoma cells compared to parental NK cells. Additionally, experiments with primary human NK cells demonstrate the potential of ApEn-NK to specifically target and kill lymphoma cells, thus presenting a potential new approach for targeted immunotherapy by NK cells.
机译:天然杀伤(NK)细胞是先天免疫系统的关键组成部分,因为它们可以在没有先前致敏的情况下攻击癌细胞。然而,由于缺乏细胞特异性受体,NK细胞并不能够进行靶向癌症免疫疗法。适体是短的单链寡核苷酸,其特异性地识别它们以与抗体类似的方式具有高亲和力的靶标。为了使NK细胞具有靶特异性,合成CD30特异性适体锚定在细胞表面上,以产生适于工程化的NK细胞(APEN-NK)而不存在遗传改变或细胞损伤。在表面锚定的适体引导下,APEN-NK特异性结合CD30表达CD30淋巴瘤细胞,但不与偏离靶细胞反应。与父母NK细胞相比,所得特异性细胞结合触发淋巴瘤细胞的更高凋亡/死亡率。另外,用初级人NK细胞的实验证明了APEN-NK至特异性靶向和杀死淋巴瘤细胞的潜力,从而呈现NK细胞的靶向免疫疗法的潜在新方法。

著录项

  • 来源
    《Small》 |2019年第22期|共11页
  • 作者单位

    Department of Hematology Xiangya Hospital Central South University Changsha 410008 Hunan China;

    Department of Pathology and Genomic Medicine Houston Methodist Hospital Houston TX 77030 USA;

    Department of Pathology and Genomic Medicine Houston Methodist Hospital Houston TX 77030 USA;

    Department of Pathology and Genomic Medicine Houston Methodist Hospital Houston TX 77030 USA;

    Department of Pathology and Genomic Medicine Houston Methodist Hospital Houston TX 77030 USA;

    Department of Pathology and Genomic Medicine Houston Methodist Hospital Houston TX 77030 USA;

    Department of Pathology and Genomic Medicine Houston Methodist Hospital Houston TX 77030 USA;

    Department of Pathology and Genomic Medicine Houston Methodist Hospital Houston TX 77030 USA;

    Department of Pathology and Genomic Medicine Houston Methodist Hospital Houston TX 77030 USA;

    Department of Pathology and Genomic Medicine Houston Methodist Hospital Houston TX 77030 USA;

    Department of Pathology and Genomic Medicine Houston Methodist Hospital Houston TX 77030 USA;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 特种结构材料;
  • 关键词

    adaptive immunotherapy; aptamer-engineering; lymphoma; natural killer (NK) cells; oligonucleotide aptamers;

    机译:自适应免疫疗法;适体 - 工程;淋巴瘤;天然杀伤(NK)细胞;寡核苷酸适体;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号